ClinicalTrials.gov Identifier: NCT04176991. Chondrial Therapeutics, Inc., November 26, 2019
Phase 1, A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia.
CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
Wednesday, November 27, 2019
Subscribe to:
Posts (Atom)
